Who pays for personalized medicine?

May 24, 2012

While researchers are busy identifying new biomarkers to detect disease and tailor treatments to individual needs, legal battles have been waged all the way up to the Supreme Court, trying to sort out whether a private company can own the rights to a particular biomarker.

In a new Perspective piece published today in the , Jason Karlawish, MD, professor of Medicine, and Health Policy in the Perelman School of Medicine at the University of Pennsylvania, and co-author Aaron S. Kesselheim, MD, JD, MPH, from Brigham and Women's Hospital and Harvard Medical School, delve into a series of high profile court cases testing the limits of .

In the months since a US Supreme Court ruling unanimously "rendered invalid two patents covering a method for determining proper drug dosage," as Nature reports, discussions have swirled about how to pay for . The NEJM co-authors report that "a patentable process now needs to involve an inventive and novel application of a law of nature beyond well-understood, routine, conventional activity, previously engaged in by those in the field."

Without patents protecting such medical discoveries, some have argued that there is no way to recoup the costs of biomarker innovation. To that end, Supreme Court Justice Breyer suggested whether special market-exclusivity protection was warranted.

Instead, the authors suggest that enhanced public funding, public-private partnerships, and open-source consortia may improve biomarker discovery and development, more than a private model. According to the NEJM piece, "the Supreme Court's move to free the fundamental processes of from private ownership…could ultimately enhance the public health."

As biomarkers become more and more prevalent -- helping diagnose diseases, and pairing with treatments targeted to individual needs -- there will need to be solutions to balance the needs of ensuring access to this useful information and paying for personalized medicine.

Explore further: Court Denies Vonage Bid for Patent Case Retrial

Related Stories

Court Denies Vonage Bid for Patent Case Retrial

May 4, 2007

A U.S. appeals court denies a request by Internet phone company Vonage Holdings that it order a retrial in the patent infringement case brought against it by Verizon Communications.

Supreme Court voting patterns show high predictability

November 9, 2011

Supreme Court rulings can dramatically shape American policies, but the Court's decisions may actually be quite predictable, according to a new study published in the Nov. 9 issue of the online journal PLoS ONE.

Recommended for you

'Business diet' a bad deal for the heart

August 19, 2016

(HealthDay)—The typical "social business diet"—heavy on red meats, sweet drinks, processed snacks and booze—takes a toll on the heart, a new study finds.

Concussion rates rising significantly in adolescents

August 18, 2016

The number of Americans diagnosed with concussions is growing, most significantly in adolescents, according to researchers at UC San Francisco. They recommend that adolescents be prioritized for ongoing work in concussion ...

Large trial proposed to compare HCTZ, chlorthalidone

August 17, 2016

(HealthDay)—A large randomized trial is being developed to compare the effectiveness of hydrochlorothiazide with chlorthalidone in Veterans Affairs (VA) patients, according to an Ideas and Opinions piece published online ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.